Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
KEYWORDS: people, treatment, anticoagulation, dvt, committee, anticoagulation treatment, evidence, vte, recommendations, risk, cancer, agreed, clinical, use, d-dimer

－ stop interim therapeutic anticoagulation, but do not stop: ◇ long-term anticoagulation when used for secondary prevention [2012], or ◇ short-term anticoagulation when used for primary VTE prevention in people with COVID-19 (see the recommendations on VTE prophylaxis in the NICE guideline on managing COVID-19) [2023] － think about alternative diagnoses [2012] － tell the person that it is not likely they have DVT. Discuss with them the signs and symptoms of DVT and when and where to seek further medical help. [2012] For a short explanation of why the committee made the 2023 recommendations and how they might affect practice, see the rationale and impact section on diagnosis and initial management in people with COVID-19. Full details of the evidence and the committee's discussion are in evidence review I: diagnosing VTE in people with COVID-19. D-dimer testing 1.1.12 When offering D-dimer testing for suspected DVT or PE, consider a point-of-care test if laboratory facilities are not immediately available. [2020] 1.1.13 If using a point-of-care D-dimer test, choose a fully quantitative test. [2020] 1.1.14 When using a point-of-care or laboratory D-dimer test, consider an age-adjusted D-dimer test threshold for people aged over 50. [2020] For a short explanation of why
